AsianScientist (Feb. 2, 2016) – WuXi AppTec Co. Ltd., an open-access R&D capability and technology platform company, has started construction on an integrated biologics solution center at the company’s headquarters in Shanghai.
The company plans to invest a total of US$120 million to build this dedicated 250,000 sq ft facility, which will be operational by 2017 and accommodate 800 scientists. The facility will provide integrated solutions from ideas to the clinic for biologics discovery, development and clinical manufacturing on a consolidated campus.
The biologics discovery center will feature the state-of-the-art OmniRatTM platform in collaboration with Open Monoclonal Technology, Inc., and in-house proprietary phage display libraries to enable global clients to discover conventional monoclonal antibodies (mAbs), bi-specific mAbs and antibody-drug conjugates.
The biologics development center will feature WuXi’s proprietary CHO cell line platform to develop robust fed-batch and perfusion processes to meet demanding processing needs. The co-located cGMP clinical manufacturing facilities will support four concurrent campaigns using 3x2000L fed-batch and 2x500L perfusion bio-reactors.
“We are very pleased to continue to invest in our biologics capabilities and expand our capacities to support the ambitious plans of our global clients,” said Dr. Ge Li, chairman and CEO of WuXi AppTec.
———
Source: Wuxi AppTec; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
